mTOR inhibitors and diabetes

详细信息    查看全文

• 作者：Bruno Verg&egrave ; s^a ; ^b ; ^e ; ^{bruno.verges@chu-dijon.fr" class="auth_mail" title="E-mail the corresponding author} ; Bertrand Cariou^b ; ^c ; ^d ; ^e
• 关键词：mTOR inhibitors ; Diabetes ; Hyperglycemia ; Cancer ; Everolimus ; Temsirolimus
• 刊名：Diabetes Research and Clinical Practice
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：110
• 期：2
• 页码：101-108
• 全文大小：800 K

文摘

The mammalian target of rapamycin (mTOR) inhibitors are drugs, primarily used as immunosuppressors that are now frequently used as antineoplastic therapies in various cancers (such as advanced renal cell carcinoma, advanced breast cancer, progressive pancreatic neuroendocrine tumors). They act on mTOR signaling pathway which plays a key role in regulating cell growth as well as lipid and glucose metabolism. Treatment with mTOR inhibitors is associated with a high incidence of hyperglycemia and new-onset diabetes, ranging from 13% to 50% in the clinical trials in which they have been used as anticancer therapies. The rate of severe hyperglycemia is also increased, ranging from 4 to 12% in the main phase III clinical trials. Due to limited human studies, the pathophysiology of mTOR inhibitor-induced hyperglycemia has not yet been totally clarified. However, data from animal studies suggest that the mechanisms responsible for hyperglycemia with mTOR inhibitors are likely due to the combination of impaired insulin secretion and insulin resistance. Due to the high rate of hyperglycemia associated with the use of mTOR inhibitors, a close and personalized follow-up of blood glucose is recommended in all patients.